Nestlé (SWX:NESN) is back in focus after announcing a collaboration with US based Helaina to explore bioactive proteins for infant formula, aiming to more closely mirror components found in human milk.
See our latest analysis for Nestlé.
The Helaina collaboration comes as momentum in Nestlé’s share price has been subdued, with the stock at CHF76.96 and a 1 year total shareholder return that declined 7.6% while the 5 year total shareholder return is down 21.0%. This suggests that investors are still weighing long term growth prospects against recent developments in areas like infant nutrition.
If this kind of product focused news has you thinking more broadly about where capital could work harder, it may be worth checking a curated list of 102 top founder-led companies
With the share price under pressure over 1 and 5 years, yet trading at a discount to analyst targets and some estimates of intrinsic value, the key question is whether this represents genuine upside or whether markets already reflect future growth.
Most Popular Narrative: 15.5% Undervalued
According to Tokyo’s widely followed narrative, Nestlé’s fair value of CHF91 sits comfortably above the last close at CHF76.96, setting up a clear valuation gap for investors to examine.
Nestlé is no longer a high-growth company, but a global compounder transforming toward higher-value nutrition categories. The key investment thesis is that Nestlé can gradually improve profitability through:
Health Science,
GLP-1 Nutrition,
Pet Care,
Premium Coffee,
and Emerging Markets.
Curious what sits behind that CHF91 figure? The narrative brings together measured revenue growth, firmer margins, and a richer earnings multiple, all grounded in detailed assumptions but far from universally agreed.
Result: Fair Value of CHF91 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this hinges on Nestlé executing in higher margin nutrition while managing slow recent shareholder returns and any shift in analyst assumptions that supports the CHF91 fair value.
Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.
Next Steps
With sentiment mixed between recent returns and potential upside, this is a moment to move quickly, review the data yourself, and weigh 3 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Nestlé has you thinking bigger about your portfolio, do not sit on the sidelines while other opportunities line up across quality, yield, and resilience.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we’re here to simplify it.
Discover if Nestlé might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com